Lipocine to present at H.C. Wainwright conference

Lipocine Inc. filed a current report to announce that the company will present and meet with investors at the H.C.

Accepted by SEC EDGAR 09/05/2025 - 04:33 PM EDT

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Lipocine Inc. filed a current report to announce that the company will present and meet with investors at the H.C. Wainwright 27th Annual Global Investor Conference. The event is scheduled for September 8–10, 2025, in New York City. The company furnished a press release with additional details as Exhibit 99.1 to the report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lipocine Inc. (LPCN) disclose in this 8-K filing?

Lipocine Inc. disclosed that it will present and meet with investors at the H.C. Wainwright 27th Annual Global Investor Conference and furnished a related press release as Exhibit 99.1.

When and where is Lipocine Inc. (LPCN) presenting to investors?

Lipocine Inc. is presenting and meeting with investors at the H.C. Wainwright 27th Annual Global Investor Conference from September 8–10, 2025, in New York City, New York.

Which exhibit did Lipocine Inc. (LPCN) include with this 8-K?

The company included Exhibit 99.1, a press release announcing its participation in the H.C. Wainwright 27th Annual Global Investor Conference, and Exhibit 104, the cover page interactive data file.

Does this Lipocine Inc. (LPCN) 8-K announce any financing or major transaction?

No, this report focuses on Lipocine Inc.’s planned presentation and investor meetings at a conference and does not describe any financing or major transaction.

Who signed this Lipocine Inc. (LPCN) 8-K report?

The report was signed on behalf of Lipocine Inc. by Mahesh V. Patel, the company’s President and Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

September 5, 2025

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware

99-0370688

(State or other jurisdiction

of incorporation)

(IRS Employer

Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13©(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LPCN		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events

On September 5, 2025, the Company issued a press release announcing that it is presenting and meeting with investors at the H.C. Wainwright 27^th Annual Global Investor Conference September 8-10, 2025, in New York City, New York. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

The following exhibits are filed with this report:

Exhibit No.		Description
99.1		Press Release announcing the Company to Present at the H.C. Wainwright 27^th Annual Global Investor Conference
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		LIPOCINE INC.

Date:	September 5, 2025	By:	/s/ Mahesh V. Patel
			Mahesh V. Patel
			President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR